معرفی
Sam Butterworth is a Professor of Medicinal Chemistry at the University of Manchester, holding the Chair in Medicinal Chemistry. Previously, he worked at the University of Birmingham (2013-2016) and AstraZeneca (2005-2013), where his research contributed to the development of osimertinib (Tagrisso), an FDA-approved anti-cancer drug targeting EGFR mutations. He leads the Butterworth Group, focusing on synthetic and biological chemistry to address human health challenges, particularly cancer therapy and drug delivery systems.
- Education & Experience: Senior Lecturer at Manchester (2016-2024), AstraZeneca R&D (2005-2013), Birmingham academic role (2013-2016)
- Key Projects: ERK5 inhibitors for breast cancer, nanoparticle drug delivery, and HDX mass spectrometry for protein dynamics
Research Interests: Medicinal chemistry, synthetic organic methods, targeted cancer therapies, nanoparticle systems, and enzyme modulators (e.g., NAMPT). His group collaborates closely with clinicians and biomedical researchers to validate compounds in disease models.
Publications: Over 25 peer-reviewed articles in journals like Angewandte Chemie and Acta Pharmaceutica Sinica B, focusing on catalytic methods, drug design, and nanotechnology.
- Awards: 2017 RSC Malcolm Campbell Award, 2018 ACS Heroes of Chemistry Award
- Grants/Leadership: Co-Investigator on projects totaling £[X] funding, including EPSRC and Wellcome Trust grants
Labs & Teams: Active in Manchester’s Institute of Inflammation and Repair and collaborates with the Christie NHS Foundation Trust for translational cancer research.
